Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the pharmacokinetic and pharmacodynamic and safety properties of Somatin (5 mg/1.5 ml cartridges, AryaTinaGene Biopharmaceutical Co) in comparison to Norditropin (5 mg/1.5 ml cartridges, Novo Nordisk) in healthy volunteers

Next Previous
X
Search
Trial Profile

Study of the pharmacokinetic and pharmacodynamic and safety properties of Somatin (5 mg/1.5 ml cartridges, AryaTinaGene Biopharmaceutical Co) in comparison to Norditropin (5 mg/1.5 ml cartridges, Novo Nordisk) in healthy volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin (Primary)
  • Indications Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Focus Pharmacokinetics
  • Sponsors AryaTinaGene Biopharmaceuticals

    • Most Recent Events

    • 04 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top